These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31486954)

  • 1. Rebalancing metal dyshomeostasis for Alzheimer's disease therapy.
    Yang GJ; Liu H; Ma DL; Leung CH
    J Biol Inorg Chem; 2019 Dec; 24(8):1159-1170. PubMed ID: 31486954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metal Ions in Alzheimer's Disease: A Key Role or Not?
    Liu Y; Nguyen M; Robert A; Meunier B
    Acc Chem Res; 2019 Jul; 52(7):2026-2035. PubMed ID: 31274278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyphenols as Potential Metal Chelation Compounds Against Alzheimer's Disease.
    Lakey-Beitia J; Burillo AM; La Penna G; Hegde ML; Rao KS
    J Alzheimers Dis; 2021; 82(s1):S335-S357. PubMed ID: 32568200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of chelating compounds on Cu
    Mazur T; Malik M; Bieńko DC
    J Inorg Biochem; 2024 Aug; 257():112601. PubMed ID: 38744143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper-mediated β-amyloid toxicity and its chelation therapy in Alzheimer's disease.
    Singh SK; Balendra V; Obaid AA; Esposto J; Tikhonova MA; Gautam NK; Poeggeler B
    Metallomics; 2022 Jun; 14(6):. PubMed ID: 35333348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zinc takes the center stage: its paradoxical role in Alzheimer's disease.
    Cuajungco MP; Fagét KY
    Brain Res Brain Res Rev; 2003 Jan; 41(1):44-56. PubMed ID: 12505647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity.
    Tõugu V; Tiiman A; Palumaa P
    Metallomics; 2011 Mar; 3(3):250-61. PubMed ID: 21359283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of metal dyshomeostasis in Alzheimer's disease.
    Bonda DJ; Lee HG; Blair JA; Zhu X; Perry G; Smith MA
    Metallomics; 2011 Mar; 3(3):267-70. PubMed ID: 21298161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives.
    Fasae KD; Abolaji AO; Faloye TR; Odunsi AY; Oyetayo BO; Enya JI; Rotimi JA; Akinyemi RO; Whitworth AJ; Aschner M
    J Trace Elem Med Biol; 2021 Sep; 67():126779. PubMed ID: 34034029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-beta metal interaction and metal chelation.
    Cuajungco MP; Frederickson CJ; Bush AI
    Subcell Biochem; 2005; 38():235-54. PubMed ID: 15709482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators.
    Chen LL; Fan YG; Zhao LX; Zhang Q; Wang ZY
    Bioorg Chem; 2023 Feb; 131():106301. PubMed ID: 36455485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition metal chelator therapy--a potential treatment for Alzheimer's disease?
    Gnjec A; Fonte JA; Atwood C; Martins RN
    Front Biosci; 2002 Apr; 7():d1016-23. PubMed ID: 11897554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and Opportunities of Metal Chelation Therapy in Trace Metals Overload-Induced Alzheimer's Disease.
    Chaudhari V; Bagwe-Parab S; Buttar HS; Gupta S; Vora A; Kaur G
    Neurotox Res; 2023 Jun; 41(3):270-287. PubMed ID: 36705861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of metals as therapeutic targets in Alzheimer's disease.
    Finefrock AE; Bush AI; Doraiswamy PM
    J Am Geriatr Soc; 2003 Aug; 51(8):1143-8. PubMed ID: 12890080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Strategies for Modulating Aβ Aggregation with Multifunctional Agents.
    Du Z; Li M; Ren J; Qu X
    Acc Chem Res; 2021 May; 54(9):2172-2184. PubMed ID: 33881820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metal chelation as a potential therapy for Alzheimer's disease.
    Cuajungco MP; Fagét KY; Huang X; Tanzi RE; Bush AI
    Ann N Y Acad Sci; 2000; 920():292-304. PubMed ID: 11193167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory Activity Of Curcumin Derivatives Towards Metal-free And Metal-induced Amyloid-β Aggregation.
    Kochi A; Lee HJ; Vithanarachchi SM; Padmini V; Allen MJ; Lim MH
    Curr Alzheimer Res; 2015; 12(5):415-23. PubMed ID: 25938870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease, metal ions and metal homeostatic therapy.
    Zatta P; Drago D; Bolognin S; Sensi SL
    Trends Pharmacol Sci; 2009 Jul; 30(7):346-55. PubMed ID: 19540003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents.
    Domingo JL
    J Alzheimers Dis; 2006 Nov; 10(2-3):331-41. PubMed ID: 17119296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cu and Zn interactions with Aβ peptides: consequence of coordination on aggregation and formation of neurotoxic soluble Aβ oligomers.
    Rana M; Sharma AK
    Metallomics; 2019 Jan; 11(1):64-84. PubMed ID: 30234208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.